ADC Therapeutics SA - notizie pubblicate 183 - letture 4.748
ADC THERAPEUTICS SA
Initial Registration Statement for Employee Benefit Plan - Form S-8
As filed with the securities and exchange commission on march 15, 2023 registration no. 333-__________ united states securities and exchange commission washington, d.c. 20549 form ...
ADC THERAPEUTICS SA
ADC Therapeutics Releases its Annual Report on Form 20-F for the Fiscal Year Ended December 31, 2022
The text version of this document is not available. you can access the original document here. attachments original link original document permalink disclaimer adc therapeutics sa ...
ADC THERAPEUTICS SA
Annual Report - Form 6-K
Table of contents adc therapeutics sa 2022 annual report annual report 1 table of contents table of contents letter to shareholders 3 business update 5 financial review 59 corporat ...
ADC THERAPEUTICS SA
Annual Report for Fiscal Year Ending December 31, 2022 (Form 20-F)
Table of contents united states securities and exchange commission washington, d.c. 20549 form 20-f (mark one) ☐ registration statement pursuant to section 12(b) or (g) of the se ...
ADC THERAPEUTICS SA
Current Report by Foreign Issuer - Form 6-K
Information contained in this report on form 6-k adc therapeutics sa does not hold deposits or securities at silicon valley bank. attachments original link original document permal ...
ADC THERAPEUTICS SA
ADC Therapeutics to Participate in the Cowen 43rd Annual Health Care Conference
Lausanne, switzerland--(business wire)-- adc therapeutics sa (nyse: adct) announced today that ameet mallik, chief executive officer, will present a company overview at the cowen 4 ...
ADC THERAPEUTICS SA
ADC Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Updates
Zynlonta® (loncastuximab tesirine-lpyl) net sales of $19.8 million in q4 2022, +16.5% year-over-year, and $74.9 million for the full year (fy) 2022 fy 2023 zynlonta net sales expe ...
ADC THERAPEUTICS SA
ADC Therapeutics to Host Fourth Quarter and Year-End 2022 Financial Results Conference Call on February 28, 2023
Lausanne, switzerland--(business wire)-- adc therapeutics sa (nyse: adct) today announced that it will host a conference call and live webcast on tuesday, february 28, 2023 at 8:30 ...
ADC THERAPEUTICS SA
Biopôle Route de la Corniche 3B 1066 Epalinges Switzerland - Form 6-K
Biopôle route de la corniche 3b 1066 epalinges switzerland february 2, 2023 a.t. holdings ii sàrl ritter house p.o. box 4041 wickhams cay ii road town, tortola, bvi vg1110 this l ...
ADC THERAPEUTICS SA
Supplemental Prospectus - Form 424B7
Filed pursuant to rule 424(b)(7) registration no. 333-256807 prospectus supplement (to prospectus dated june 4, 2021) adc therapeutics sa 12,000,000 common shares the selling share ...
ADC THERAPEUTICS SA
ADC Therapeutics Announces Pricing of Underwritten Offering by a Selling Shareholder
Lausanne, switzerland--(business wire)-- adc therapeutics sa ("adct" or the "company") (nyse: adct), a commercial-stage biotechnology company helping to improve ...
ADC THERAPEUTICS SA
Current Report by Foreign Issuer - Form 6-K
United states securities and exchange commission washington, d.c. 20549 form 6-k report of foreign private issuer pursuant to rule 13a-16 or 15d-16 under the securities exchange ac ...
ADC THERAPEUTICS SA
ADC Therapeutics to Participate in February Investor Conferences
Lausanne, switzerland--(business wire)-- adc therapeutics sa (nyse: adct) announced today that ameet mallik, chief executive officer, will participate in two investor conferences i ...
ADC THERAPEUTICS SA
Current Report by Foreign Issuer - Form 6-K
The text version of this document is not available. you can access the original document here. attachments original link original document permalink disclaimer adc therapeutics sa ...
ADC THERAPEUTICS SA
ADC Therapeutics to Participate in the 41st Annual J.P. Morgan Healthcare Conference - Form 6-K
Adc therapeutics to participate in the 41st annual j.p. morgan healthcare conference lausanne, switzerland, january 4, 2023 - adc therapeutics sa (nyse: adct) announced today that ...
Sei un professionista?
Abbiamo ricevuto 2.400 richieste di consulenza, pubblica il tuo profilo premium
per ricevere contatti e acquisire nuovi clienti